PLAY PODCASTS
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
Episode 199

Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma

Listen to this audio podcast with expert insights and overview of the latest data for immune checkpoint inhibitors for advanced or metastatic hepatocellular carcinoma (HCC), for intermediate HCC in combination with TACE, and the latest guidelines for high-risk early HCC.

Decera Clinical Education Oncology Podcast · Joseph W. Franses MD PhD, Neehar Parikh MD MS, Mark Yarchoan MD

July 18, 202531m 19s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including:

  • Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC
  • Overview of the Latest Data for the Combination of TACE With Immunotherapy (eg, EMERALD-1 Study of TACE and Durvalumab ± Bevacizumab for Unresectable HCC; and LEAP-012 Study of TACE + Lenvatinib + Pembrolizumab) 
  • Latest Clinical Data and Updates for Systemic Therapy in Patients With High-Risk Early HCC


Program faculty:

Joseph W. Franses, MD, PhD
Assistant Professor of Medicine
Section of Hematology-Oncology
University of Chicago
Chicago, Illinois

Neehar Parikh, MD, MS
Associate Professor
Li Ka Shing Research Professor of Hepatology
Clinical Director of Hepatology
Medical Director, Liver Tumor Program
Division of Gastroenterology & Hepatology
University of Michigan
Ann Arbor, Michigan

Mark Yarchoan, MD
Associate Professor
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, Maryland
 

Resources:
To access the resources associated with this podcast discussion, please visit the program page to access a recording from a live webinar and a frequently-asked questions commentary on this topic.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

immune checkpoint inhibitors for hccintermediate hccmdnivolumabpembrolizumabmultidisciplinary careimbrave050lenvatinibhepatocellular carcinomaemerald-1joseph w. fransesleap-012bclc bmsipilimumabbarcelona clinic liver cancerneehar parikhtacebevacizumabmark yarchoangastrointestinal cancersimmunotherapyphddurvalumabhcctareatezolizumablaunch